Chulalongkorn University reveals good news for the ChulaCov19 COVID-19 vaccine, a Thai nationality, has produced the first lot in the country and has applied for FDA approval to test in people. If good results will be registered
On May 4, 65, Prof. Dr. Kiat Rakrungtham Director of Project Management for COVID-19 Vaccine Development Project, Vaccine Research Center Faculty of Medicine Chulalongkorn University gave an interview regarding the progress of the development of the “ChulaCov19” vaccine of the Thai nationality type mRNA that the overall picture is good news. The first phase of development was to design the vaccine and have the factory in the United States produce the first lot. There is good news that it has been proven safe in Phase 1 and 2 volunteers. It stimulates the immune system to be highly satisfactory. The dosage we chose compared to the Pfizer vaccine approved for use in Thailand. We have clearly higher landscapes.
The second phase is the production of vaccines in the country by Bionet Asia Company Limited, which is a factory in Thailand. The first batch of vaccines was already produced. passed quality assurance The research team has submitted various documents and information to the Food and Drug Administration (FDA) to request testing in phase 1 and 2 subjects, pending approval by the FDA. Expect to receive a response soon if Tested according to the set goals should be able to apply for vaccine registration by the end of 2022
“Now the epidemic situation in the country is getting better. But vaccine development has not stopped. We would like to see 3 types of first-generation vaccines produced by Thai people that are currently being developed: CU mRNA vaccine, leaflet vaccine, and GPO vaccine.
If you can register first for one type or all of them, the better. The first batch of vaccines according to the procedure should be registered first. Proven to be safe During the application for registration, the second generation was developed to prevent Omicron at the same time. to wait for the next registration,” said Prof. Dr. Kiat.
Prof. Dr. Kiat continued that Thailand has our own technology. Since the invention, design, testing and production in the factory in the country make us self-reliant If the outbreak of covid comes back once more no matter which species Or a new disease outbreak occurs, we will be able to develop a vaccine by ourselves in a faster time. because we can develop the whole chain by ourselves
“If Thai vaccines can be registered within this year must rely on all sectors to support each other But vaccine production has to be done in stages. Proven efficiency and safety The main objective of Thailand’s vaccine development is to be self-reliant. Help distribute vaccines to neighboring countries faster.
If there is an epidemic and we have technology from upstream, midstream to downstream, when an epidemic occurs We will be able to do it faster, inventing, designing, producing and testing phase 1 and 2 humans in less than 6 months, not over a year like now. because the chain is not yet fully integrated,” said Prof. Dr. Kiat.
